MFN.se

Sverre Hærem has, at his own request, chosen to step down from his position as EVP & CFO of Sentia ASA. Sverre Hærem has been a valuable member of Sentia's group executive management. He has played an important role in the company's successful IPO process and served as the group's CFO during an important phase for the group. "Sverre has made a significant contribution to Sentia, and we would like to thank him for everything he has contributed.

Sverre Hærem har etter eget ønske valgt å fratre sin stilling som Konserndirektør finans og CFO. Sverre Hærem har vært et verdifullt medlem av konsernledelsen i Sentia. Han har spilt en viktig rolle i selskapets vellykkede IPO-prosess og vært konsernets CFO i en viktig fase for konsernet. "Sverre har gjort en betydelig innsats for Sentia, og vi vil takke Sverre for det han har bidratt med. Vi ønsker ham alt godt videre", sier konsernsjef Jan Jahren.

Bioretec Ltd. | Inside information | 5 September 2026 at 12:25 p.m. EEST Bioretec Ltd ("Bioretec" or the "Company"), a pioneer in bioabsorbable orthopedic implants, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its ActivaScrew™ Cannulated COM bioabsorbable compression screw. The clearance enables the commercialization of the product in the United States in accordance with its cleared indications for use.

Bioretec Oy | Sisäpiiritieto | 5.9.2026 klo 12.25 Biohajoavien ortopedisten implanttien edelläkävijä Bioretec Oy ("Bioretec" tai "Yhtiö") on saanut Yhdysvaltain elintarvike- ja lääkeviranomaiselta (FDA) 510(k)-markkinointiluvan ActivaScrew™ Cannulated COM -biohajoavalle kompressioruuville. Markkinointilupa mahdollistaa tuotteen kaupallistamisen Yhdysvalloissa hyväksytyn käyttöaiheen mukaisesti.

IMPORTANT NOTICE – DISCLAIMER Not for release or distribution or publication in whole or in part, directly or indirectly, in or into Australia, Canada, Japan or the Republic of South Africa. These materials do not contain or constitute an offer for sale or the solicitation of an offer to purchase securities in the United States, Australia, Canada, Japan or the Republic of South Africa.

Emission och återköp av E-aktier Studsvik AB (publ) meddelar att bolaget har beslutat att genomföra nyemission samt därefter omedelbart återköpa högst 7 500 E1-E6 2026-aktier, innefattandes 1 250 E1 2026-aktier, 1 250 E2 2026-aktier, 1 250 E3 2026-aktier, 1 250 E4 2026-aktier, 1 250 E5 2026-aktier och 1 250 E6 2026-aktier samt högst 120 000 E7 2026-aktier.

Issue and repurchase of class E shares Studsvik AB (publ) announces that the company has resolved to issue and immediately thereafter repurchase up to 7,500 Class E1-E6 2026 shares, comprising of 1,250 Class E1 2026 shares, 1,250 Class E2 2026 shares, 1,250 Class E3 2026 shares, 1,250 Class E4 2026 shares, 1,250 Class E5 2026 shares and 1,250 Class E6 2026 shares as well as up to 120,000 Class E7 2026 shares.

Neola Medical AB (publ) today announces that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for Neola®, the Company’s medical device for non-invasive, continuous lung monitoring in preterm born babies, with the intended use to support timely detection of potentially life-threatening lung collapse. The designation represents a significant regulatory and strategic milestone for Neola Medical and its U.S. regulatory pathway.

Emittent 971300-0165 Lundin Gold Inc. Instrument CA5503711080 Ordinary Shares, Securities lending with right to recall, and Swap on ordinary shares. Innehavare The Goldman Sachs Group Inc.

Oslo, Norway - September 04, 2026. Reference is made to the stock exchange announcements published by Nordic Mining ASA ("Nordic Mining" or the "Company") and its subsidiary Engebø Rutile and Garnet AS ("ERG") on 7 August 2026 regarding the Company's production ramp-up, liquidity situation and regulatory status. As of today, Nordic Mining continues constructive dialogues with bondholders regarding a near-term financing solution through a potential tap issue.